J&J: green light for Varipulse platform in Japan
' At Biosense Webster, we are working to offer a differentiated range of PAF integrated with 3D cardiac mapping to meet the real and unmet needs of electrophysiologists and the patients they treat. Today, we celebrate this important milestone in the approval of the Varipulse platform, the first and only PFA system approved in Japan ', said Jasmina Brooks, President of Biosense Webster.
''We are delighted to continue advancing PFA clinical studies globally, and look forward to the positive impact this innovation will have on patients worldwide,'' she added.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction